GB2341551A - Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder - Google Patents

Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder

Info

Publication number
GB2341551A
GB2341551A GB9926916A GB9926916A GB2341551A GB 2341551 A GB2341551 A GB 2341551A GB 9926916 A GB9926916 A GB 9926916A GB 9926916 A GB9926916 A GB 9926916A GB 2341551 A GB2341551 A GB 2341551A
Authority
GB
United Kingdom
Prior art keywords
treatment
pharmaceutical composition
transfer factor
regressive
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9926916A
Other versions
GB9926916D0 (en
Inventor
Andrew Jeremy Wakefield
Hugh Fundenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Free Hospital School of Medicine
NEUROIMMUNO THERAPEUTICS RESEA
Original Assignee
Royal Free Hospital School of Medicine
NEUROIMMUNO THERAPEUTICS RESEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711663.6A external-priority patent/GB9711663D0/en
Application filed by Royal Free Hospital School of Medicine, NEUROIMMUNO THERAPEUTICS RESEA filed Critical Royal Free Hospital School of Medicine
Priority to GB9928642A priority Critical patent/GB2347742B/en
Publication of GB9926916D0 publication Critical patent/GB9926916D0/en
Publication of GB2341551A publication Critical patent/GB2341551A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention concerns a pharmaceutical composition for the treatment of an MMR virus mediated disease comprising a soluble dialysed leucocyte extract comprising a transfer factor (TF) formed by the dialysis of virus-specific lymphocytes to a molecular weight filter cut-off of 12,500 disposed in a pharmaceutically acceptable carrier or diluent therefor.
GB9926916A 1997-06-05 1998-06-04 Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder Withdrawn GB2341551A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9928642A GB2347742B (en) 1997-06-05 1998-06-04 Pharmaceutical composition for RBD

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711663.6A GB9711663D0 (en) 1997-06-05 1997-06-05 Pharmaceutical composition for treatment of IBD and RBD
PCT/GB1998/001637 WO1998055138A1 (en) 1997-06-05 1998-06-04 Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder

Publications (2)

Publication Number Publication Date
GB9926916D0 GB9926916D0 (en) 2000-01-12
GB2341551A true GB2341551A (en) 2000-03-22

Family

ID=10813634

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9926916A Withdrawn GB2341551A (en) 1997-06-05 1998-06-04 Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder
GB9812056A Withdrawn GB2325856A (en) 1997-06-05 1998-06-04 Pharmaceutical composition for treatment of MMR virus mediated disease comprising a transfer factor obtained from the dialysis of virus-specific lymphocytes

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9812056A Withdrawn GB2325856A (en) 1997-06-05 1998-06-04 Pharmaceutical composition for treatment of MMR virus mediated disease comprising a transfer factor obtained from the dialysis of virus-specific lymphocytes

Country Status (5)

Country Link
US (1) US6534259B1 (en)
AU (1) AU7780598A (en)
CA (1) CA2328503A1 (en)
GB (2) GB2341551A (en)
WO (1) WO1998055138A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000348321A (en) * 1999-06-03 2000-12-15 Nec Corp Magnetic disk device, magnetic head, manufacture of magnetic head, and manufacture of magnetic disk device
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20060073197A1 (en) * 2004-05-20 2006-04-06 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US20070128253A1 (en) * 2005-04-13 2007-06-07 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20090053197A1 (en) * 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
US20090074751A1 (en) * 2007-09-18 2009-03-19 Ramaekers Nutrition, Inc. Growth factor fraction compositions and methods
EP2278984A4 (en) * 2007-11-30 2013-02-27 Ramaekers Family Trust Compositions and methods for enhancing fertility
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
DK3064217T3 (en) 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
JP5976100B2 (en) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010738A1 (en) * 1978-10-25 1980-05-14 A/S Alfred Benzon Transfer factor and method for producing same
EP0101200A2 (en) * 1982-07-20 1984-02-22 BIO-COM Inc. Transfer factor for use in treating viral infections
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
WO1996030544A1 (en) * 1995-03-28 1996-10-03 Andrew Jeremy Wakefield Diagnostic and therapeutic system for crohn's disease and colitia ulcerosa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US5874226A (en) * 1995-05-22 1999-02-23 H. Lee Browne In situ immunodetection of antigens
US5883224A (en) * 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
AUPP537198A0 (en) 1998-08-21 1998-09-10 Polygon Pty Ltd As Trustee For Polygon Unit Trust A system for treating materials for separation
US6720122B1 (en) 1999-06-28 2004-04-13 Zeon Corp. Toner for developing static charge image and method for preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010738A1 (en) * 1978-10-25 1980-05-14 A/S Alfred Benzon Transfer factor and method for producing same
EP0101200A2 (en) * 1982-07-20 1984-02-22 BIO-COM Inc. Transfer factor for use in treating viral infections
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
WO1996030544A1 (en) * 1995-03-28 1996-10-03 Andrew Jeremy Wakefield Diagnostic and therapeutic system for crohn's disease and colitia ulcerosa

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gut Vol. 20 (5) 1979. Vicary F R et.al. pages 408-413 *
In Vivo Vol. 8 (4) 1994. Ferrer-Argote V E et.al. pages 555-557 *
The Lancet Vol. 345 1995. Thompson N P et.al. pages 1071-1074 *

Also Published As

Publication number Publication date
CA2328503A1 (en) 1998-12-10
AU7780598A (en) 1998-12-21
US6534259B1 (en) 2003-03-18
GB9926916D0 (en) 2000-01-12
GB9812056D0 (en) 1998-08-05
GB2325856A (en) 1998-12-09
WO1998055138A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
GB2341551A (en) Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder
DE69835201D1 (en) Neoglycoproteine
YU94802A (en) 3-prodrugs of 2'-deoxy-beta-l-nucleosides
HUP0300121A3 (en) Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them
EA199901031A1 (en) Derivatives of benzimidazole
DZ2009A1 (en) New taxoids, their preparation and the pharmaceutical compositions containing them.
FR2716893B1 (en) Recombinant viruses, their preparation and their therapeutic use.
BG100974A (en) Vaccines against papillomavirus
IL101425A0 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus,methods for their use and pharmaceutical compositions containing the same
AU652941B2 (en) Non-A, Non-B hepatitis virus particles
BG102809A (en) Vaccine against the reproductive and respiratory syndrome in pigs
FR2773994B1 (en) PRODUCTS FROM HUMAN IMMUNODEFICIENCY VIRUS INHIBITORS OF ANTI-PROTEASES FOR IMPROVED BIODAVAILABILITY, TROPISM TO AND / OR DELIVERY IN THE CENTRAL NERVOUS SYSTEM
DE69724453D1 (en) CAMPTOTHECINE ANALOGA, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
FR2712288B1 (en) New taxoids, their preparation and the pharmaceutical compositions containing them.
HUP0003174A3 (en) 20(s) camptothecin glycoconjugates, process for their preparation and pharmaceutical compositions containing them
ZA978351B (en) Immunogenic peptides of foot-and-mouth disease viruses.
HUP9802042A3 (en) Taxoids, preparation thereof, and pharmaceutical compositions containing same
FR2721023B1 (en) New Taxoids, their preparation and the pharmaceutical compositions containing them.
NO931246L (en) COMPOSITIONS FOR TREATING INFECTION AND DISEASE CAUSED BY HEPATITES B VIRUS (HBV)
IL99543A0 (en) Oligonucleotides,pharmaceutical compositions containing the same and methods for detection of herpes virus utilizing the same
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
DE69726602D1 (en) Hepatitis b inhibitoren
FR2711369B1 (en) New taxoids, their preparation and the compositions containing them.
戚中田 et al. Studies on hepatitis C virus and prevalence of its infection in China
ZA904546B (en) A composition for removing or inactivating harmful components in blood or other extracellular body fluids

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)